A news item about a biotech advancing a novel glycan-targeting antibody-drug conjugate into first-in-human clinical testing, explaining the trial’s purpose and early development context.
Key Takeaways
- First patient was dosed in the GNX1021 first-in-human Phase I trial in Japan
- GNX1021 targets the branched Lewis B/Y glycan antigen commonly expressed in gastrointestinal cancers
- Multinational trial in Japan and Taiwan will evaluate safety